Synopsis
========

Introduction:
-------------

*E-cadherin* (CDH1) is expressed on the cell surface in most epithelial tissues \[[@B1],[@B2]\], and evidence is rapidly accumulating that the mammalian *E-cadherin* gene product plays a role in epithelial tumourigenesis \[[@B3]\]. Germline mutations in *E-cadherin* have been described in families with early-onset diffuse gastric cancer, and loss of function of this gene has been implicated in the pathogenesis of early-onset colorectal and breast cancers. Despite the fact that *E-cadherin* expression is decreased in 50% of invasive ductal carcinoma \[[@B4]\], mutations in the coding sequence of *E-cadherin* have not been observed in this type of breast cancer \[[@B5],[@B6]\]. The role of *E-cadherin* mutation in development of hereditary gastric cancer has been shown, but its role in predisposing to breast cancer is still unproved. In order to further explore the involvement of E-cadherin in breast cancer, we examined all 16 exons of *E-cadherin* in 31 familial breast cancer patients, in whom *BRCA1* and *BRCA2* had been excluded as predisposing genes \[[@B7],[@B8],[@B9]\].

In a previous study of a family with diffuse gastric cancer (Fig. [1a](#F1){ref-type="fig"}) (Salahshor S, *et al*, manuscript submitted), we identified an *E-cadherin* germline mutation that cosegregated with the disease. This missense mutation in exon 12 (Ala592Thr) was also detected in the index patient\'s mother, who had ductal breast cancer. In an attempt to clarify a possible role for the Ala592Thr alteration in predisposing to breast cancer, we screened for this specific alteration in different series of breast cancer patients and control individuals. In total, 1328 patients with sporadic or familial breast cancer and 497 control individuals were analyzed for this specific alteration.

Materials and method:
---------------------

Nineteen probands with familial breast cancer who demonstrated LOH at chromosome 16q, and 12 patients from 10 families with breast, gastric and colorectal cancers were screened for germline mutations in the coding sequences of *E-cadherin*. Nine tumours from the 19 breast cancer cases were also screened for somatic mutations. The frequencies of the 1774G→A variant (Ala592Thr) were determined in DNA extracted from the blood of 358 unrelated probands with familial breast cancer, 214 unrelated early-onset breast cancer patients (age of onset \<41 years), 126 unrelated *BRCA1* or *BRCA2* carriers, and 604 unselected breast cancer patients and 497 control individuals, who were considered to represent the general population in Sweden and Norway.

Two markers D16S7/p79-2-23 and APRT/HUAP15, which both map to 16q24.3, were used to identify LOH, as in a previous study of allelic loss at 16q in familial tumours \[[@B10]\].

Single-stranded conformation polymorphism (SSCP) and denaturing high-performance liquid chromotography (DHPLC; Transgenomic, Santa Clara, CA, USA) were used to screen 16 exons of the *E-cadherin* gene for the presence of alterations (Table [1](#T1){ref-type="table"}). We used the same primers as described by Berx *et al* \[[@B5]\] and Salahshor *et al* (manuscript submitted), but with some modification. Samples that exhibited aberrant bands on the SSCP gel or an altered DHPLC pattern were sequenced by reamplifying the corresponding exon. Sequencing was performed either manually using the ThermoSequensase (Amersham Pharmacia Biotech, Uppsala, Sweden) kit, or by 377 ABI automated sequencer using the Taq-Cycle sequencing BigDye Terminator kit (Applied Biosystems Inc ABI, Stockholm, Sweden), according to conditions recommended by the manufacturers. The Ala592Thr variant frequency was detected using specific polymerase chain reaction (PCR)-restriction fragment length polymorphism tests (Salahshor S, *et al*, manuscript submitted).

Results:
--------

No pathogenic mutations were identified in the 12 patients from families with documented breast, gastric or colon cancer. We also searched for germline alterations in 19 individuals with familial breast cancer who showed LOH at the *E-cadherin* locus in their tumours. Nine tumours from these 19 patients were also tested for somatic alterations in the *E-cadherin* gene. One somatic mutation (49-2A→C) was found in one of the lobular cancer cases (Fig. [2](#F2){ref-type="fig"}). One previously reported common polymorphism in *E-cadherin* \[[@B11]\] was found in exon 13 at codon 692 (GCC→GCT).

In a previous study in one family with familial diffuse gastric cancer and colon cancer (Fig. [1a](#F1){ref-type="fig"}) (Salahshor S, *et al*, manuscript submitted), we found a germline missense mutation in exon 12 (Ala592Thr) of *E-cadherin*. This alteration cosegregated with diffuse gastric cancer and colorectal cancer in this family, although the penetrance was not complete. The alteration was present in the index patient\'s mother, who had ductal breast cancer of comedo type at the age of 65 years (Fig. [1a](#F1){ref-type="fig"}, II:12). In order to investigate whether this alteration was associated with an increased risk for breast cancer, we used a specific restriction enzyme digestion/PCR test to detect the variant, in an allelic association study in familial and sporadic breast cancer cases, as well as control samples that represented the general population. We found the mutation in two out of 358 (0.56%) non-*BRCA1*/*BRCA2* carrier women with familial breast cancer (families 205 and 2027). In family 205 (Fig. [1b](#F1){ref-type="fig"}), one woman with ductal comedo-type breast cancer at age 75 years had the Ala592Thr variant. The other available case from this family (Figure [1b](#F1){ref-type="fig"}, II:2) tested negative, and the histology report was not available. In family 2027 (Fig. [1c](#F1){ref-type="fig"}), one woman with a breast cancer of ductal comedo type at age 37 years showed the Ala592Thr variant. Her two sisters, who had breast cancer at ages 45 and 51 years, did not. One of the sisters had lobular breast cancer, whereas the histopathological information from the third case was unavailable for study. Because the variant did not segregate with the disease, it is not likely that this alteration predisposes to breast cancer in either of these two families.

We also screened 126 *BRCA1* or *BRCA2* carriers from different families, and found the mutation in one breast cancer patient (family 4056) with a *BRCA1* germline mutation (delC2594). It was possible to obtain a sample from her sister who also carried the *BRCA1* mutation, and she was found to share the Ala592Thr variant (Fig. [1d](#F1){ref-type="fig"}). Both tumours were of ductal comedo type. Because both of these tumours were caused by a germline *BRCA1* mutation, the *E-cadherin* variant was not likely to have predisposed to breast cancer. Among the 604 sporadic breast cancer cases, five were found to carry the Ala592Thr alteration (0.83%; Table [2](#T2){ref-type="table"}). One of the tumours was of lobular type, and the other four were of ductal type. One of the ductal tumours was of comedo type, and the tumour type of the other three was not known. Four cases with Ala592Thr alteration were also found among the 497 control individuals (0.80%). The alteration was not found among any of the 214 early-onset breast cancer patients.

Discussion:
-----------

So far, *E-cadherin* germline mutations have been reported in 17 diffuse gastric cancer families \[[@B12],[@B13],[@B14],[@B15],[@B16]\]. The frequency of *E-cadherin* germline mutations in breast cancer reported thus far is low \[[@B17],[@B18]\]. Mutations reported in *E-cadherin* in lobular breast cancer patients are in most cases tumour restricted, and not germline alterations \[[@B5],[@B19]\]. In the present study, we did not find any pathogenic alteration in 10 families that included patients with breast, gastric or colon cancer. We conclude that, although germline *E-cadherin* mutations are sometimes found in familial gastric and colon cancer, they are not frequently involved in families in which gastric cancer appears to segregate as a part of an inherited predisposition to primary breast cancer.

The frequency of Ala592Thr alteration, which was first identified in one family with familial diffuse gastric cancer plus one case of colon and one case of breast cancer (Fig. [1a](#F1){ref-type="fig"}), was similar in the various groups studied here (Table [2](#T2){ref-type="table"}). This finding does not support an effect of this alteration in predisposing to breast cancer in general. Thus, available data indicate that germline *E-cadherin* mutations do not constitute a major risk factor for breast cancer. However, other studies have indicated that somatic alterations could have an impact on the phenotype in lobular breast cancer. The fact that many tumours with the alteration (Ala592Thr) in the present study were of the ductal comedo type may indicate a genetic basis for the phenotypic divergence caused by this germline *E-cadherin* alteration. Although lobular breast carcinoma and ductal breast carcinoma of comedo type are different from each other histologically, neither of these cancers are associated with good prognosis. However, individual prognosis with breast cancer is assessed mainly by grading rather than by histological type \[[@B20],[@B21]\].

In summary, the present study, together with previously reported data, suggests that a germline mutation in *E-cadherin* is not a major risk factor for breast cancer. However, germline, and more often somatic mutations in this gene could have an impact on phenotypic divergence and prognosis, including growth pattern of the tumours, such as in lobular and perhaps ductal comedo-type breast cancer. In addition, other genetic alterations or epigenetic changes in the *E-cadherin* gene may have an impact on the metastatic behaviour of the cancer cells, and thereby on the clinical outcome.

Introduction
============

*E-cadherin* (CDH1) is expressed on the cell surface in most epithelial tissues \[[@B1],[@B2]\], and evidence is rapidly accumulating that the mammalian *E-cadherin* gene product plays a role in epithelial tumourigenesis \[[@B3]\]. Loss of function in E-cadherin and/or other collaborating proteins contributes to increased proliferation, invasion and metastasis in many malignant epithelial tumours \[[@B22],[@B23]\]. Mutations in *E-cadherin*, which encodes a transmembrane protein, have been described in cancers of the endometrium and ovary \[[@B11]\], signet ring cell carcinoma of the stomach \[[@B24],[@B25]\], the diffuse sclerosing variant of papillary thyroid carcinoma \[[@B26]\], invasive lobular breast cancer \[[@B5],[@B19],[@B27],[@B28]\], and diffuse and mixed gastric cancer \[[@B24],[@B28],[@B29],[@B30]\]. *E-cadherin* germline mutations have been found in early-onset hereditary diffuse gastric cancer \[[@B12],[@B14],[@B16]\], and such mutations have even been implicated as risk factors for early-onset breast and colon cancers \[[@B13],[@B15]\]. Inactivating mutations and decreased expression of *E-cadherin* have been reported in invasive lobular breast carcinomas \[[@B5],[@B19]\], which demonstrate involvement of *E-cadherin* alteration in sporadic lobular breast cancer. Lobular carcinoma *in situ* is known to be a risk factor for breast cancer, but thus far constitutional *E-cadherin* mutations have not been identified in patients with lobular carcinoma *in situ* \[[@B18]\]. In sporadic breast cancer, a correlation between loss of *E-cadherin* expression and metastatic behaviour has been reported \[[@B4],[@B31],[@B32],[@B33]\]. Despite the fact that *E-cadherin* expression is decreased in 50% of invasive ductal carcinomas \[[@B4]\], mutations in the coding sequence of *E-cadherin* have not been observed in this type of breast cancer \[[@B5],[@B6]\].

A role of *E-cadherin* mutation in development of hereditary gastric cancer has been shown, but its role in predisposing to breast cancer is still unproved. In order to further explore the involvement of *E-cadherin* in breast cancer, we examined all 16 exons of *E-cadherin* in 31 familial breast cancer patients in whom involvement of *BRCA1* and *BRCA2* had been excluded \[[@B7],[@B8],[@B9]\]. Twelve of these breast cancer patients (from 10 families) had, besides a family history of breast cancer, a family history of gastric or colorectal cancer. The remaining 19 familial breast cancer patients were identified as having LOH at 16q in their tumour \[[@B34]\]. LOH at 16q occurs frequently in sporadic \[[@B35]\] and in familial breast cancer \[[@B10]\]. It has also been shown to correlate with distant metastasis \[[@B34],[@B36]\]. In the familial breast cancer patients in whom LOH at 16q was identified, *E-cadherin* was suggested to be a candidate predisposing tumour suppressor gene \[[@B34]\], and the aim of the present study was to elucidate this relation.

In a previous study in a family with diffuse gastric and colon cancer (Salahshor S, *et al*, manuscript submitted), we found an *E-cadherin* germline mutation that cosegregated with the disease. This missense mutation in exon 12 (Ala592Thr) was also detected in the index patient\'s mother, who had ductal breast cancer. In an attempt to clarify a possible role of the Ala592Thr alteration in predisposing to breast cancer, we screened for this specific alteration in different series of breast cancer patients and control individuals. In total, 1328 patients with sporadic or familial breast cancer and 497 control individuals were tested for this specific alteration.

Materials and method
====================

Cases
-----

### Cases screened for mutations in the E-cadherin gene

Nineteen women with breast cancer who exhibited LOH at 16q were included in the present study. All of these index patients had a positive family history (more than one first- or second-degree relative with breast cancer). Ten of the 19 cases were of ductal histology, one case was both ductal and lobular, two cases were lobular only and one case was medullar. For five other cases information regarding histology was not available \[[@B10],[@B34]\]. Nine tumours (four ductal, two lobular, one with both ductal and lobular, and two cases with unknown histology) from these 19 patients were also tested for somatic mutations in *E-cadherin*.

In order to examine whether germline mutations in *E-cadherin* are involved in familial breast, gastric and colon cancer, 12 patients from 10 such families were also included in the present study. Six of those 12 cases had breast cancer, five had colon cancer, and one was affected with both breast and colon cancer. The histology of the breast and gastric cancers in this group was not available for study.

### Individuals genotyped for the Ala592Thr variant

The frequencies of Ala592Thr variant were determined in DNA extracted from blood of 358 probands with familial breast cancer, 214 unrelated early-onset breast cancer patients (age of onset \<41 years), 126 unrelated *BRCA1* or *BRCA2* carriers, and 604 unselected breast cancer patients from consecutive series. In addition 497 control patients were genotyped, who were considered to represent the general populations of Sweden and Norway. The Norwegian control individuals (a total of 244) included 177 healthy female individuals obtained through the Norwegian Population Registry as a population-based series of women aged 20-44 years from the Oslo area, and 67 healthy women (aged 55-79 years) from a mammographic screening programme from Bergen area. The Swedish control individuals (a total of 253) were healthy relatives of individuals who were counseled at the Karolinska hospital.

In the present study, \'familial breast cancer cases\' are defined as patients with more than one first- or second-degree relative with breast cancer, regardless of age. All familial cases had already been tested for germline mutations in the *BRCA1* and *BRCA2* genes.

### Determination of loss of heterozygosity

In the previous study of allelic loss at 16q in familial tumours \[[@B10]\] the two markers D16S7/p79-2-23 and APRT/HUAP15, which map to 16q24.3, were used. Both markers are distal to *E-cadherin*.

Mutation analysis
-----------------

### Polymerase chain reaction/single-stranded conformation polymorphism

SSCP was used to screen 16 exons of the *E-cadherin* gene for the presence of alterations, as described by Berx *et al* \[[@B5]\] and Salahshor *et al* (manuscript submitted), but with some modification.

### Denaturing high-performance liquid chromatography

DHPLC was carried out on automated instrumentation equipped with a DNA-separation column (Wave^®^ system; Transgenomic). PCR and Taq Gold^™^ enzyme (Applied Biosystems Inc ABI) were used to amplify all 16 exons of *E-cadherin* (96°C, 15 min; 94°C, 30 s; 50-70°C, 30 s; 72°C, 45 s for 30 cycles; 72°C, 2 min). The primers used were as described previously \[[@B5]\] (Salahshor S, *et al*, manuscript submitted). Heteroduplexes and homoduplexes were formed when the PCR products were hybridized by heating to 95°C (for 5 min) and cooling slowly (by 1.5°C/min, 47 cycles). Five microlitres of each PCR product were then analyzed using the Wave^®^ system (Transgenomic). DNA was eluted with a mixture of bufferA (0.1 mol/l triethylamine acetate) and buffer B (0.1 mol/l triethylamine acetate, 25% acetonitrile) at a flow rate of 0.9 ml/min. The mobile-phase gradients and the temperatures for running each exon were suggested by the Wave-Maker software (Transgenomic), based on the sequence contents. The temperatures at which PCR products were analyzed are given in Table [1](#T1){ref-type="table"}. The results were analyzed using HSM7000 software (Transgenomic).

### Sequencing

Samples with an aberrant band on the SSCP gel or an altered DHPLC pattern were sequenced by reamplifying the corresponding exon. Sequencing was performed either manually using the ThermoSequensase (Amersham Corp) kit, or with the 377 ABI automated sequencer using the Taq-Cycle sequencing BigDye Terminator kit (Applied Biosystems Inc) according to the standard conditions recommended by the manufacturer.

### Restriction enzyme digestion

The Ala592Thr variant was detected using a specific PCR-restriction fragment length polymorphism test. In short, two pairs of primers, E-CAD12F (TGTCTGATGT-GAATGACAGC) and E-CAD12R (TGCTGTGAAGGGAGATGTAT) were used for amplification of nucleotides 1574-1884 of *E-cadherin* (based on GenBank accession number Z13009). The forward primer generates an *in vitro* mutation at nucleotide 1772 (A→G), leading to an Hha I restriction site in the PCR product. If the endogenous mutation 1774 (G→A) is present, then the Hha I restriction endonuclease site is lost. Mutated samples are distinguished from normal samples by a 20-bp longer uncleaved exon 12 fragment on agarose gels (Salahshor S, *et al*, manuscript submitted).

Results
=======

Screening for *E-cadherin* germline alterations in familial breast cancer
-------------------------------------------------------------------------

The entire coding region of the *E-cadherin* gene was studied, including splice sites, using PCR/SSCP and sequencing in 10 families with histories of breast, gastric and colon cancer. No pathogenic germline mutation was identified in any of the individuals screened.

Negative results were also obtained by screening for germline alterations in 19 individuals with familial breast cancer who exhibited LOH at the *E-cadherin* locus in their tumours. We also searched for somatic alterations in nine of these 19 cases in whom tumours were available for analysis using Wave^®^ (Transgenomic), an HLPC-based nucleic acid fragment analysis system. One somatic mutation in an exon 2 splicing site (49-2A→C) was detected in the tumour that was of both ductal and lobular histology (Fig. [2](#F2){ref-type="fig"}). Clinical outcomes of these 19 patients were available, with 5-12 years of follow up. The two lobular breast cancer patients had both developed distant metastases, whereas distant metastases had developed in five out of 10 patients with ductal breast cancer. The patient with ductal-lobular histology and the mutation did not have distant metastasis 8 years after surgery. One previously reported common polymorphism in *E-cadherin* \[[@B11]\] was found in exon13 at codon 692 (GCC→GCT).

The frequency of the Ala592Tyr missense alteration
--------------------------------------------------

In a previous study of one family (family 26) with familial colon and gastric cancer (Fig. [1a](#F1){ref-type="fig"}) (Salahshor S, *et al*, manuscript submitted), we identified a germline missense alteration in exon12 (Ala592Thr) of *E-cadherin*. This alteration cosegregated with diffuse gastric cancer and colorectal cancer in this family, although the penetrance was not complete. The alteration was present in the index patient\'s mother, who had ductal breast cancer of comedo type at age 65 years (Figure [1a](#F1){ref-type="fig"}, II:12). In order to investigate whether this alteration was associated with an increased breast cancer risk we used a specific restriction enzyme digestion/PCR test to detect the variant, in an allelic association study of familial and sporadic breast cancer patients as well as control individuals who were considered to represent the general population.

We found the mutation in two out of 358 (0.56%) non-*BRCA1*/*BRCA2* carrier women with familial breast cancer (families 205 and 2027). In family 205 (Fig. [1b](#F1){ref-type="fig"}), one woman with ductal comedo-type breast cancer at age 75 years had the Ala592Thr variant. The other available case from this family (Fig. [1b](#F1){ref-type="fig"}, II:2) tested negative, and the histology report was not available. In family 2027 (Fig. [1c](#F1){ref-type="fig"}), one woman with a breast cancer of ductal comedo type at age 37 years exhibited the Ala592Thr variant, whereas her two sisters with breast cancer at ages 45 and 51 years did not. One of the sisters had lobular breast cancer, but histopathological information on the third case was not available. Because the variant did not segregate with the disease, it is not likely that this alteration predisposes to breast cancer in either of these two families.

We also screened 126 *BRCA1* or *BRCA2* carriers from different families, and identified the mutation in one patient with breast cancer (family 4056) with a *BRCA1* germline mutation (2594delC). It was possible to obtain a sample from her sister who also carried the *BRCA1* mutation, and she was found to share the Ala592Thr variant also (Fig. [1d](#F1){ref-type="fig"}). Both tumours were of ductal comedo type. Because both of these tumours were caused by a germline *BRCA1* mutation, the *E-cadherin* variant was not likely to have predisposed to breast cancer.

Among the 604 sporadic breast cancer patients, five were found to carry the Ala592Thr alteration (0.83%; Table [2](#T2){ref-type="table"}). One of these was of lobular type and the other four were of ductal type. One of the ductal tumours was of comedo type, but it was not known for the other three whether they were of comedo type. Four cases with Ala592Thr alteration were also found among the 497 control patients (0.80%). The alteration was not found among any of the 214 early-onset breast cancer patients.

Discussion
==========

*E-cadherin* germline mutations in familial breast cancer
---------------------------------------------------------

Thus far, *E-cadherin* germline mutations have been reported in 17 diffuse gastric cancer families \[[@B12],[@B13],[@B14],[@B15],[@B16]\]. The high rate of mutations found in the Maori families probably reflects the criteria used for selection of the families. In these families at least three first-degree relatives were affected by gastric cancer, and the age of onset of at least one case was under 40 years. In other studies, a low frequency of *E-cadherin* germline mutations in familial gastric cancer has been reported \[[@B37],[@B38]\]. The frequency of *E-cadherin* germline mutations in breast cancer reported thus far is low \[[@B17],[@B18]\]. Mutations in *E-cadherin* reported in lobular breast cancer cases are in most cases tumour restricted, and are not germline alterations \[[@B5],[@B19]\]. In the 17 gastric cancer families with germline mutations, five members from three families were also affected by breast cancer \[[@B13],[@B17]\]. Three of these patients from three different families had both breast and gastric cancer. One patient had developed both lobular breast cancer and diffuse-type gastric cancer \[[@B17]\]. In the other cases the gastric cancers were of diffuse type, and the histology of the breast tumours was unknown \[[@B13]\]. In one of these families, two patients with breast cancer only were also found; these cases were early-onset breast cancer.

In the present study, we did not find any pathogenic alterations in 10 families with cases of breast, gastric or colon cancer. We conclude that, although germline *E-cadherin* mutations are sometimes found in familial gastric and colon cancer, they are not frequently involved in families in which breast cancer appears to segregate as a part of an inherited predisposition for gastric and colon cancer.

Ala592Tyr alteration and breast cancer of ductal comedo type
------------------------------------------------------------

The frequency of Ala592Thr alteration, which was first identified in one family with familial diffuse gastric, colon and breast cancer (Fig. [1a](#F1){ref-type="fig"}), was almost the same in the different groups studied here (Table [2](#T2){ref-type="table"}). In familial breast cancer cases the frequency was 0.56% in non-*BRCA1/BRCA2* cases, and 0.79% in *BRCA1* or *BRCA2* carriers. In the sporadic cases and in the control population, the frequencies were 0.83 and 0.80%, respectively. This finding does not support an effect of this alteration in predisposing to breast cancer in general. Thus, available data thus far indicate that germline *E-cadherin* mutations do not constitute a major risk factor for breast cancer. However, it is quite clear that somatic alterations can have an impact on the phenotype in lobular breast cancer. The fact that many breast cancer cases with the alteration (Ala592Thr) in the present study were of the ductal comedo type may indicate a genetic basis for the phenotypic divergence caused by this germline *E-cadherin* alteration. Although lobular breast carcinoma and ductal breast carcinoma of comedo type differ in many respects histologically, both lack formation of more differentiated mammary gland structures such as tubules. In lobular cancer, the cell characteristically grows in thin single-cell files (so-called Indian files). The comedo cancer is a poorly differentiated ductal cancer, which is rich in mitoses, often with large intraductal masses of cells with central necroses (comedons). Neither of these cancers carry a good prognosis, but individual prognosis with breast cancer is assessed mainly by grading rather than by histological type \[[@B20],[@B21]\].

Correlation between loss of heterozygosity at 16q, tumourigenesis and metastasis in breast cancer
-------------------------------------------------------------------------------------------------

If *E-cadherin* functions as a classical tumour suppressor gene, then loss or inactivation of the remaining normal *E-cadherin* allele would be an important event in tumourigenesis in individuals who carry a germline mutation. In tumours with somatic *E-cadherin* mutations, there is often evidence of deletion of the wild-type *E-cadherin* allele \[[@B19]\], whereas in cases with germline mutations in the *E-cadherin* gene this is not usually seen \[[@B13],[@B15],[@B17]\]. We did not find any germline mutations in the 19 familial breast cancer cases with LOH at 16q studied here, which indicates that *E-cadherin* does not act as a predisposing factor for breast cancer in these families. In order to examine whether somatic alterations in this gene are involved in the carcinogenesis of these tumours, we screened for somatic mutations in nine available tumours from these cases, and we found one somatic mutation in one of the lobular cancer cases. In cases with no mutation in *E-cadherin*, however, inactivation of this gene could have been achieved by a variety of other mechanisms. Genetic alterations in any component of the cadherin--catenin complex appear to induce loss of adhesion function \[[@B39],[@B40]\]. Furthermore, epigenetic changes such as promoter region hypermethylation, post-transcriptional alteration and aberrant phosphorylation of members of the cadherin-catenin complex can dysregulate E-cadherin function \[[@B41],[@B42],[@B43],[@B44]\]. It is also possible that other gene(s) located at 16q are altered, rather than *E-cadherin*.

Conclusion
==========

This present study, together with previously reported data, suggests that a germline mutation in *E-cadherin* is not a major risk factor for breast cancer. However, germline, and more often somatic mutations in this gene probably have an impact on phenotypic divergence and prognosis, including growth patterns of tumours, such as in lobular and perhaps ductal comedo breast cancers. In addition, other genetic alterations or epigenetic events at the *E-cadherin* gene may have an impact on the metastatic behaviour of the cancer cells, and thereby on the clinical outcome.

Abbrevations
============

DHPLC = denaturing high-performance liquid chromatography; LOH = loss of heterozygosity; PCR = polymerase chain reaction; SSCP = single-stranded conformation polymorphism.

Figures and Tables
==================

![Pedigrees of the four families with Ala592Thr missense alteration. BR, breast cancer; GA, gastric cancer; OV, ovarian cancer; GI, gastrointestinal cancer; AD, colonic adenomas; Endo, endometrial cancer; M, positive for the Ala592Thr variant; N, wild-type E-cadherin.](BCR-3-3-199-1){#F1}

![The 3\' splice site alteration in the *E-cadherin* gene (49-2A→C) in tumor M279.](BCR-3-3-199-2){#F2}

###### 

PCR and DHPLC conditions for the mutational analysis of *E-cadherin*

       Annealing   Amplicon   DHPLC
  ---- ----------- ---------- ------------
  1    70          285        66
  2    55          377        62
  3    60          352        58, 61
  4    60          351        60
  5    60          398        58
  6    58          246        59
  7    60          329        60, 62, 64
  8    58          225        59, 62
  9    55          252        59
  10   55          309        58
  11   60          243        61
  12   60          326        59, 61
  13   58          297        58
  14   60          206        61
  15   60          244        58
  16   60          318        59

###### 

Frequency of Ala592Thr variant in various populations of breast cancer patients and control population

                                          No of families/   Frequency of             
  --------------------------------------- ----------------- -------------- --------- ---------------
  Familial breast cancer                                                             
   Non-*BRCA1*/*BRCA2* mutation carrier   358               0.56%          311-89D   Ductal comedo
                                                                           AL-155    Ductal comedo
   *BRCA1*/*BRCA2* carrier                126               0.79%          BR-115    Ductal comedo
                                                                           BR-119    Ductal comedo
  Sporadic breast cancer                                                             
   Early-onset breast cancer              214               \-                       
   Unselected breast cancer               604               0.83%          17-S      Lobular
                                                                           MB-181    Ductal comedo
                                                                           MB-483    Ductal
                                                                           ULL-17    Ductal
                                                                           ULL-284   Ductal
  Control population                      495               0.80%                    
